With the accumulated evidence about SIRT1's function in cancer, EX-527 and other SIRT inhibitors have been studied as potential therapies in multiple cancer cells, including melanoma 35, hepatocellular carcinoma 36, chronic lymphocytic leukemia 37, and lung cancer 38. Here, SIRT1 is linked to lung carcinoma.